Publisher Summary This chapter describes the assembly, release, and maturation of human
immunodeficiency virus type 1 (HIV-1). The HIV‐1 replication cycle has the potential to …

Formation of infectious HIV-1 involves assembly of Gag polyproteins into immature particles
and subsequent assembly of mature capsids after proteolytic disassembly of the Gag shell …

The capsid domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is a
critical determinant of virus assembly, and is therefore a potential target for developing drugs …

Many compounds able to interfere with HIV-1 infection have been identified; some 25 of
them have been approved for clinical use. Current anti-HIV-1 therapy involves the use of …

HIV-1 capsid protein (CA) plays important roles in the viral replication cycle. A number of
acylhydrazone derivatives that act as inhibitors of HIV-1 CA assembly, were designed and …

The hydrophobic cavity of the C-terminal domain (CTD) of HIV-1 capsid has been recently
validated as potential target for antiviral drugs by peptide-based inhibitors; however, there is …

This study investigates whether the biochemical and antiviral effects of organic compounds
that bind different sites in the mature human immunodeficiency virus capsid may be related …

In previous studies, thermodynamic dissection of the dimerization interface in CA-C, the C-
terminal domain of the capsid protein of human immunodeficiency virus type 1, revealed that …

Highly active antiretroviral therapy (HAART) has markedly decreased mortality and morbidity
in the developed world. HAART consists of a combination of three or more of the following …

Although combinations of drugs that target the HIV reverse transcriptase and protease
enzymes have clearly revolutionized the treatment of HIV/AIDS, problems with these agents …